-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Tigermed released the 2021 annual performance forecast.
The announcement showed that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies increased compared with the same period last year
.
The announcement showed that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies increased compared with the same period last year
.
The forecast shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 2.
625-3.
027 billion yuan, a year-on-year increase of 50%-73%
.
It is estimated that the net profit after deducting non-return to the parent is 1.
133-1.
324 billion yuan, a year-on-year increase of 60%-87%
.
The non-recurring gains and losses in 2021 were RMB 1.
4-1.
8 billion, mainly due to the gains from changes in the fair value of financial assets recognized by the company in accordance with the new financial instrument standards and gains from equity transfers
.
625-3.
027 billion yuan, a year-on-year increase of 50%-73%
.
It is estimated that the net profit after deducting non-return to the parent is 1.
133-1.
324 billion yuan, a year-on-year increase of 60%-87%
.
The non-recurring gains and losses in 2021 were RMB 1.
4-1.
8 billion, mainly due to the gains from changes in the fair value of financial assets recognized by the company in accordance with the new financial instrument standards and gains from equity transfers
.
The financial assets invested by the company are mainly biopharmaceuticals, medical devices and other companies related to the company's main business and medical and health professional investment funds.
The gains from changes in fair value recognized by the Financial Instruments Standards are RMB 1.
2-1.
6 billion
.
The gains from changes in fair value recognized by the Financial Instruments Standards are RMB 1.
2-1.
6 billion
.
Tigermed performance forecast table
Source: Company Announcement
In terms of investment, the company has established a diversified investment portfolio and actively deployed industrial chain opportunities related to its own business.
Previously, the company announced that from 2014 to 2021, Tigermed participated in 26 medical investment funds or investments with 1.
3 billion yuan.
For partnerships, the average capital contribution of each fund is 50 million yuan
.
By investing in these funds, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies
.
Previously, the company announced that from 2014 to 2021, Tigermed participated in 26 medical investment funds or investments with 1.
3 billion yuan.
For partnerships, the average capital contribution of each fund is 50 million yuan
.
By investing in these funds, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies
.
"CRO + investment" two-wheel drive performance growth
Tigermed's main business focuses on clinical CRO integrated services, and drives continuous growth in performance through a model that matches investment and main business
.
From 2014 to 2021, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies through its investment funds.
Now Tigermed has established its own direct investment fund, and the investment will be greater, and the control of the project will also be reduced.
will be stronger, and investment business has always been an important part of Tigermed’s strategy
.
.
From 2014 to 2021, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies through its investment funds.
Now Tigermed has established its own direct investment fund, and the investment will be greater, and the control of the project will also be reduced.
will be stronger, and investment business has always been an important part of Tigermed’s strategy
.
The chairman of the company, Ye Xiaoping, said at the shareholders' meeting in May this year that a relatively large fund of funds may be established in five years, and the overall investment amount will become larger and larger
.
It is said that in addition to the fund, Tigermed will increase the scale of direct investment this year.
Currently, it is recruiting a team of 20 to 30 people and will invest 5 to 6 billion yuan
.
.
It is said that in addition to the fund, Tigermed will increase the scale of direct investment this year.
Currently, it is recruiting a team of 20 to 30 people and will invest 5 to 6 billion yuan
.
The direct result of Tigermed's strategic change is that the financing war in the entire innovative drug industry will heat up again.
Tigermed's active attack will likely lead to direct competition with WuXi AppTec and several leading innovations.
Strategies of pharmaceutical companies have changed
.
By investing in "zoning out", it is the core goal of several companies to make their respective ecosystems more complete and their moats wider
.
Tigermed's active attack will likely lead to direct competition with WuXi AppTec and several leading innovations.
Strategies of pharmaceutical companies have changed
.
By investing in "zoning out", it is the core goal of several companies to make their respective ecosystems more complete and their moats wider
.
Future Investment Outlook
The company's outlook and layout for the next ten years of China's pharmaceutical investment business in the future, Tigermed is more like a platform, investment is divided into three levels, 100% holding Hangzhou Tigermed, Tigermed as GP fund and LP fund, major shareholder Individual investment, through the combination of listed company investment in relatively stable projects + fund investment plus leverage + personal venture investment, under the condition of controllable risks, maximize investment returns
.
.
The CXO industry is still in a high level of prosperity, with multiple business segments developing collaboratively.
As a leading clinical CRO in China, the company continues to benefit from the dividends of domestic innovative drug research and development.
At the same time, the clinical research and development projects have been weakened by the impact of the epidemic, and the company's main business has gradually resumed
.
In addition, the company continues to improve the layout and extension of the industrial chain, and accelerate the construction of an international multi-center clinical platform with the help of the new crown vaccine to go overseas
.
As a leading clinical CRO in China, the company continues to benefit from the dividends of domestic innovative drug research and development.
At the same time, the clinical research and development projects have been weakened by the impact of the epidemic, and the company's main business has gradually resumed
.
In addition, the company continues to improve the layout and extension of the industrial chain, and accelerate the construction of an international multi-center clinical platform with the help of the new crown vaccine to go overseas
.
Recently, Tigermed released the 2021 annual performance forecast.
The announcement showed that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies increased compared with the same period last year
.
The announcement showed that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies increased compared with the same period last year
.
The forecast shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 2.
625-3.
027 billion yuan, a year-on-year increase of 50%-73%
.
It is estimated that the net profit after deducting non-return to the parent is 1.
133-1.
324 billion yuan, a year-on-year increase of 60%-87%
.
The non-recurring gains and losses in 2021 were RMB 1.
4-1.
8 billion, mainly due to the gains from changes in the fair value of financial assets recognized by the company in accordance with the new financial instrument standards and gains from equity transfers
.
625-3.
027 billion yuan, a year-on-year increase of 50%-73%
.
It is estimated that the net profit after deducting non-return to the parent is 1.
133-1.
324 billion yuan, a year-on-year increase of 60%-87%
.
The non-recurring gains and losses in 2021 were RMB 1.
4-1.
8 billion, mainly due to the gains from changes in the fair value of financial assets recognized by the company in accordance with the new financial instrument standards and gains from equity transfers
.
The financial assets invested by the company are mainly biopharmaceuticals, medical devices and other companies related to the company's main business and medical and health professional investment funds.
The gains from changes in fair value recognized by the Financial Instruments Standards are RMB 1.
2-1.
6 billion
.
The gains from changes in fair value recognized by the Financial Instruments Standards are RMB 1.
2-1.
6 billion
.
Tigermed performance forecast table
Source: Company Announcement
In terms of investment, the company has established a diversified investment portfolio and actively deployed industrial chain opportunities related to its own business.
Previously, the company announced that from 2014 to 2021, Tigermed participated in 26 medical investment funds or investments with 1.
3 billion yuan.
For partnerships, the average capital contribution of each fund is 50 million yuan
.
By investing in these funds, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies
.
Previously, the company announced that from 2014 to 2021, Tigermed participated in 26 medical investment funds or investments with 1.
3 billion yuan.
For partnerships, the average capital contribution of each fund is 50 million yuan
.
By investing in these funds, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies
.
"CRO + investment" two-wheel drive performance growth
Tigermed's main business focuses on clinical CRO integrated services, and drives continuous growth in performance through a model that matches investment and main business
.
From 2014 to 2021, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies through its investment funds.
Now Tigermed has established its own direct investment fund, and the investment will be greater, and the control of the project will also be reduced.
will be stronger, and investment business has always been an important part of Tigermed’s strategy
.
.
From 2014 to 2021, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies through its investment funds.
Now Tigermed has established its own direct investment fund, and the investment will be greater, and the control of the project will also be reduced.
will be stronger, and investment business has always been an important part of Tigermed’s strategy
.
The chairman of the company, Ye Xiaoping, said at the shareholders' meeting in May this year that a relatively large fund of funds may be established in five years, and the overall investment amount will become larger and larger
.
It is said that in addition to the fund, Tigermed will increase the scale of direct investment this year.
Currently, it is recruiting a team of 20 to 30 people and will invest 5 to 6 billion yuan
.
.
It is said that in addition to the fund, Tigermed will increase the scale of direct investment this year.
Currently, it is recruiting a team of 20 to 30 people and will invest 5 to 6 billion yuan
.
The direct result of Tigermed's strategic change is that the financing war in the entire innovative drug industry will heat up again.
Tigermed's active attack will likely lead to direct competition with WuXi AppTec and several leading innovations.
Strategies of pharmaceutical companies have changed
.
By investing in "zoning out", it is the core goal of several companies to make their respective ecosystems more complete and their moats wider
.
Tigermed's active attack will likely lead to direct competition with WuXi AppTec and several leading innovations.
Strategies of pharmaceutical companies have changed
.
By investing in "zoning out", it is the core goal of several companies to make their respective ecosystems more complete and their moats wider
.
Future Investment Outlook
The company's outlook and layout for the next ten years of China's pharmaceutical investment business in the future, Tigermed is more like a platform, investment is divided into three levels, 100% holding Hangzhou Tigermed, Tigermed as GP fund and LP fund, major shareholder Individual investment, through the combination of listed company investment in relatively stable projects + fund investment plus leverage + personal venture investment, under the condition of controllable risks, maximize investment returns
.
.
The CXO industry is still in a high level of prosperity, with multiple business segments developing collaboratively.
As a leading clinical CRO in China, the company continues to benefit from the dividends of domestic innovative drug research and development.
At the same time, the clinical research and development projects have been weakened by the impact of the epidemic, and the company's main business has gradually resumed
.
In addition, the company continues to improve the layout and extension of the industrial chain, and accelerate the construction of an international multi-center clinical platform with the help of the new crown vaccine to go overseas
.
As a leading clinical CRO in China, the company continues to benefit from the dividends of domestic innovative drug research and development.
At the same time, the clinical research and development projects have been weakened by the impact of the epidemic, and the company's main business has gradually resumed
.
In addition, the company continues to improve the layout and extension of the industrial chain, and accelerate the construction of an international multi-center clinical platform with the help of the new crown vaccine to go overseas
.
Recently, Tigermed released the 2021 annual performance forecast.
The announcement showed that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies increased compared with the same period last year
.
The announcement showed that Tigermed's expected 2021 revenue and net profit attributable to shareholders of listed companies increased compared with the same period last year
.
The forecast shows that the net profit attributable to shareholders of listed companies in 2021 is expected to be 2.
625-3.
027 billion yuan, a year-on-year increase of 50%-73%
.
It is estimated that the net profit after deducting non-return to the parent is 1.
133-1.
324 billion yuan, a year-on-year increase of 60%-87%
.
The non-recurring gains and losses in 2021 were RMB 1.
4-1.
8 billion, mainly due to the gains from changes in the fair value of financial assets recognized by the company in accordance with the new financial instrument standards and gains from equity transfers
.
625-3.
027 billion yuan, a year-on-year increase of 50%-73%
.
It is estimated that the net profit after deducting non-return to the parent is 1.
133-1.
324 billion yuan, a year-on-year increase of 60%-87%
.
The non-recurring gains and losses in 2021 were RMB 1.
4-1.
8 billion, mainly due to the gains from changes in the fair value of financial assets recognized by the company in accordance with the new financial instrument standards and gains from equity transfers
.
The financial assets invested by the company are mainly biopharmaceuticals, medical devices and other companies related to the company's main business and medical and health professional investment funds.
The gains from changes in fair value recognized by the Financial Instruments Standards are RMB 1.
2-1.
6 billion
.
The gains from changes in fair value recognized by the Financial Instruments Standards are RMB 1.
2-1.
6 billion
.
Tigermed performance forecast table
Source: Company Announcement
In terms of investment, the company has established a diversified investment portfolio and actively deployed industrial chain opportunities related to its own business.
Previously, the company announced that from 2014 to 2021, Tigermed participated in 26 medical investment funds or investments with 1.
3 billion yuan.
For partnerships, the average capital contribution of each fund is 50 million yuan
.
By investing in these funds, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies
.
Previously, the company announced that from 2014 to 2021, Tigermed participated in 26 medical investment funds or investments with 1.
3 billion yuan.
For partnerships, the average capital contribution of each fund is 50 million yuan
.
By investing in these funds, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies
.
"CRO + investment" two-wheel drive performance growth
"CRO + investment" two-wheel drive performance growth Tigermed's main business focuses on clinical CRO integrated services, and drives continuous growth in performance through a model that matches investment and main business
.
From 2014 to 2021, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies through its investment funds.
Now Tigermed has established its own direct investment fund, and the investment will be greater, and the control of the project will also be reduced.
will be stronger, and investment business has always been an important part of Tigermed’s strategy
.
.
From 2014 to 2021, Tigermed has indirectly participated in the financing of hundreds of innovative pharmaceutical companies through its investment funds.
Now Tigermed has established its own direct investment fund, and the investment will be greater, and the control of the project will also be reduced.
will be stronger, and investment business has always been an important part of Tigermed’s strategy
.
The chairman of the company, Ye Xiaoping, said at the shareholders' meeting in May this year that a relatively large fund of funds may be established in five years, and the overall investment amount will become larger and larger
.
It is said that in addition to the fund, Tigermed will increase the scale of direct investment this year.
Currently, it is recruiting a team of 20 to 30 people and will invest 5 to 6 billion yuan
.
.
It is said that in addition to the fund, Tigermed will increase the scale of direct investment this year.
Currently, it is recruiting a team of 20 to 30 people and will invest 5 to 6 billion yuan
.
The direct result of Tigermed's strategic change is that the financing war in the entire innovative drug industry will heat up again.
Tigermed's active attack will likely lead to direct competition with WuXi AppTec and several leading innovations.
Strategies of pharmaceutical companies have changed
.
By investing in "zoning out", it is the core goal of several companies to make their respective ecosystems more complete and their moats wider
.
Tigermed's active attack will likely lead to direct competition with WuXi AppTec and several leading innovations.
Strategies of pharmaceutical companies have changed
.
By investing in "zoning out", it is the core goal of several companies to make their respective ecosystems more complete and their moats wider
.
Future Investment Outlook
Future Investment Outlook The company's outlook and layout for the next ten years of China's pharmaceutical investment business in the future, Tigermed is more like a platform, investment is divided into three levels, 100% holding Hangzhou Tigermed, Tigermed as GP fund and LP fund, major shareholder Individual investment, through the combination of listed company investment in relatively stable projects + fund investment plus leverage + personal venture investment, under the condition of controllable risks, maximize investment returns
.
.
The CXO industry is still in a high level of prosperity, with multiple business segments developing collaboratively.
As a leading clinical CRO in China, the company continues to benefit from the dividends of domestic innovative drug research and development.
At the same time, the clinical research and development projects have been weakened by the impact of the epidemic, and the company's main business has gradually resumed
.
In addition, the company continues to improve the layout and extension of the industrial chain, and accelerate the construction of an international multi-center clinical platform with the help of the new crown vaccine to go overseas
.
As a leading clinical CRO in China, the company continues to benefit from the dividends of domestic innovative drug research and development.
At the same time, the clinical research and development projects have been weakened by the impact of the epidemic, and the company's main business has gradually resumed
.
In addition, the company continues to improve the layout and extension of the industrial chain, and accelerate the construction of an international multi-center clinical platform with the help of the new crown vaccine to go overseas
.
